Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) has been given an average rating of “Hold” by the seven research firms that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $16.33.
Several research analysts recently commented on the stock. HC Wainwright set a $11.00 price target on shares of Foamix Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, September 18th. ValuEngine downgraded shares of Foamix Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, October 4th. BidaskClub downgraded shares of Foamix Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, October 27th. Cantor Fitzgerald assumed coverage on shares of Foamix Pharmaceuticals in a research note on Thursday, October 11th. They issued an “overweight” rating on the stock. Finally, Zacks Investment Research downgraded shares of Foamix Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 8th.
A number of institutional investors have recently modified their holdings of the business. Nexthera Capital LP bought a new position in Foamix Pharmaceuticals during the 3rd quarter worth about $4,282,000. Point72 Asset Management L.P. bought a new position in Foamix Pharmaceuticals during the 3rd quarter worth about $6,616,000. Sio Capital Management LLC bought a new position in Foamix Pharmaceuticals during the 3rd quarter worth about $4,412,000. Hound Partners LLC bought a new position in Foamix Pharmaceuticals during the 3rd quarter worth about $1,117,000. Finally, Perceptive Advisors LLC grew its holdings in Foamix Pharmaceuticals by 178.1% during the 3rd quarter. Perceptive Advisors LLC now owns 3,107,424 shares of the specialty pharmaceutical company’s stock worth $17,806,000 after acquiring an additional 1,990,100 shares in the last quarter. Institutional investors own 49.63% of the company’s stock.
Foamix Pharmaceuticals (NASDAQ:FOMX) last posted its quarterly earnings results on Wednesday, November 7th. The specialty pharmaceutical company reported ($0.38) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.07). The company had revenue of $0.87 million during the quarter, compared to analysts’ expectations of $1.10 million. Foamix Pharmaceuticals had a negative return on equity of 118.29% and a negative net margin of 2,049.92%. As a group, analysts predict that Foamix Pharmaceuticals will post -1.65 earnings per share for the current fiscal year.
Foamix Pharmaceuticals Company Profile
Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations primarily for the treatment of moderate-to-severe acne, moderate-to-severe papulo-pustular rosacea, and other skin conditions in the United States and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline, which has completed a double-blind and dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus.
Read More: What is the 52-week high/low?
Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.